bimagrumab semaglutide combination trial nct Results of “BELIEVE” redefine the rules for GLP1RA therapies: lose fat, keep muscles. + Trial tested (Wegovy) with Bimagrumab, a novel monoclonal antibody treatment treatment for preserving muscle + 22 % Emerging Role of Myostatin Inhibitors

This does not prove treatment of insulin resistance or diabetes in people

You can always eat again in 2-3 hours if you're actually still hungry

Hydrating : With its high water content, it helps keep you hydrated, which is vital, especially when taking medications like Wegovy that may lead to gastrointestinal discomfort

H., Tey, Y

Both semaglutide and tirzepatide can help lower inflammation levels in the body

The triple-receptor approach extends the metabolic research effects of single-receptor (semaglutide) and dual-receptor (tirzepatide) predecessors by adding glucagon receptor activity which contributes to additional metabolic and energy expenditure pathways